Miravo Healthcare™ Announces Appointment of Dale MacCandlish Weil to its Board of Directors

MISSISSAUGA, Ontario–(BUSINESS WIRE)–Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Dale MacCandlish Weil to its Board of Directors (Board).

Mrs. Weil was nominated to join the Board and subsequently appointed during the proceedings of the Miravo Healthcare Annual General Meeting of Shareholders convened on May 16, 2022.

Dale MacCandlish Weil is currently the Executive Director of the Teresa Dellar Palliative Care Residence and Montreal Institute for Palliative Care. She is also a Director for Theratechnologies and Tetra Bio-Pharma. From 1999 to 2018, Mrs. Weil was with McKesson Canada Corporation, holding leadership roles including Senior Vice President Integrated Healthcare and Pharmaceutical Solutions, Senior Vice President Integrated Healthcare Solutions, Strategy and Business Development, and Senior Advisor to the President. Prior to joining McKesson Canada, Mrs. Weil spent 20 years at John Labatt Ltd., Ault Foods and Parmalat Canada in progressive roles in marketing, strategy, sales, and general management. Mrs. Weil holds a BSC in Marine Biology, an MBA from McGill University and is a certified director from the ICD Directors Education Program.

Jesse Ledger, President & Chief Executive Officer of Miravo commented, “We are pleased to welcome Dale as a member of our Board of Directors. Her experience in the healthcare industry and her engagements on various boards will provide invaluable insights as we continue to execute on our strategy.”

Rob Harris, Chair of the Board commented, “On behalf of the Company and the Board of Directors, I would like to thank David Copeland, our outgoing director, for his years of service on the Board in the capacity of Lead Director and Chair of the Audit Committee.”

About Miravo Healthcare

Miravo is a Canadian-focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company’s products target several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S., Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.

Contacts

Investor Relations

Stefan Eftychiou

905 326 1888 ext 60

[email protected]